CVS Health's massive acquisition of Aetna could face heightened regulatory scrutiny amid the Trump administration's new regulatory regime. Aetna's stock is trading about 10% below the per-share offer price, reflecting investor uncertainty that the deal will get approval. A year ago, CVS Health's $69 billion acquisition of Aetna would've probably skated past regulatory proceedings. But things have changed under the Trump administration, and investors don't look particularly confident...
READ FULL ARTICLE »
Become a member to take advantage of more features, like commenting and voting.
Register or sign in today!